US 12,466,795 B2
Isoindoline compositions and methods for treating neurodegenerative disease
Gilbert M. Rishton, Los Angeles, CA (US); Susan M. Catalano, Pittsburgh, PA (US); and Gary C. Look, Santa Clara, CA (US)
Assigned to Cognition Therapeutics, Inc., Pittsburgh, PA (US)
Filed by Cognition Therapeutics, Inc., Pittsburgh, PA (US)
Filed on Apr. 27, 2023, as Appl. No. 18/308,037.
Application 18/308,037 is a continuation of application No. 16/783,943, filed on Feb. 6, 2020, granted, now 11,691,947.
Application 16/783,943 is a continuation of application No. 16/230,238, filed on Dec. 21, 2018, granted, now 10,611,728, issued on Apr. 7, 2020.
Application 16/230,238 is a continuation of application No. 15/700,923, filed on Sep. 11, 2017, granted, now 10,207,991, issued on Feb. 19, 2019.
Application 15/700,923 is a continuation of application No. 15/115,187, granted, now 9,796,672, issued on Oct. 24, 2017, previously published as PCT/US2015/013754, filed on Jan. 30, 2015.
Claims priority of provisional application 61/934,528, filed on Jan. 31, 2014.
Prior Publication US 2024/0150288 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/44 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/407 (2006.01); A61K 31/496 (2006.01); A61P 25/00 (2006.01); C07D 209/62 (2006.01); C07D 403/06 (2006.01); C07D 491/048 (2006.01); C07D 491/056 (2006.01)
CPC C07D 209/44 (2013.01) [A61K 31/4035 (2013.01); A61P 25/00 (2018.01); C07D 209/62 (2013.01); C07D 403/06 (2013.01); C07D 491/048 (2013.01); C07D 491/056 (2013.01)] 6 Claims
 
1. A pharmaceutical composition comprising 10 to 2000 mg of a compound of the Formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.